Key facts
- Synapsis Labs’s last known valuation is $5.9M.
- It has raised $260K.
- Notable investors include Pfizer CDI.
- Status: Privately Held (backing).
Investors
1- ·The complete investor list — 1 names
- ·Watchlist + deal alerts for Synapsis Labs
- ·The full record, as it builds
Funding rounds
No funding rounds for Synapsis Labs are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Synapsis Labs
Developer of an AI-powered healthcare technology platform designed to revolutionize diagnostics by improving accuracy, eliminating human error and accelerating processing speed to support better patient outcomes. The company offers advanced AI-driven diagnostic services that deliver greater accuracy and efficiency than traditional methods, enabling customers to streamline workflows, reduce misdiagnoses and provide faster, more precise patient care.
- Sector
- Information Technology
- HQ
- Markopoulo Mesogeas, Greece
- Founded
- 2024
- Employees
- 3
- Website
- synapsis.cc/
- Ownership
- Privately Held (backing)
Synapsis Labs doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Synapsis Labs shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Synapsis Labs in its N-PORT filings yet. We sweep new filings monthly.